Drugs / MET-4
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT05743777 | May 2023 | head and neck squamous cell carcinoma | Canadian Cancer Trials Group | Withdrawn | No outcome recorded Stop: Business |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT03686202 | Nov 2018 → Dec 2024 overdue | high grade malignant neoplasm | University Health Network, Toronto | Active not recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT03838601 | Jul 2019 → Sep 2025 | head and neck squamous cell carcinoma | University Health Network, Toronto | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MET-4 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03686202 ↗ |
| Modality | Other / unclassified | “MET consists of a defined mixture of pure live cultures of intestinal bacteria isolated from a stool sample of a healthy donor.” NCT03686202 ↗ |
| Route | Oral | “MET-4 is administered orally as an initial daily loading dose (5g) of MET-4 over 2 days followed by a daily maintenance dose (1.5g) of MET-4 and will be continued until...” NCT03686202 ↗ |